<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080678</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000354505</org_study_id>
    <secondary_id>MDA-ID-030008</secondary_id>
    <secondary_id>NOVARTIS-MDA-ID-030008</secondary_id>
    <secondary_id>MSKCC-03132</secondary_id>
    <secondary_id>DFCI-03187</secondary_id>
    <nct_id>NCT00080678</nct_id>
  </id_info>
  <brief_title>Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases</brief_title>
  <official_title>Randomized Double-Blind Phase II Trial of Docetaxel and Imatinib Versus Docetaxel and Placebo in Metastatic Androgen-Independent Prostate Cancer (AIPC) With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth&#xD;
      of tumor cells by blocking the enzymes necessary for their growth. Combining docetaxel with&#xD;
      imatinib mesylate may be effective treatment for androgen-independent prostate cancer and&#xD;
      bone metastases.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying docetaxel and imatinib mesylate to see&#xD;
      how well they work compared to docetaxel alone in treating patients with androgen-independent&#xD;
      prostate cancer and bone metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare time to progression in patients with androgen-independent prostate cancer and&#xD;
           bone metastases treated with docetaxel with vs without imatinib mesylate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response rates in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxic effects of these regimens in these patients.&#xD;
&#xD;
        -  Compare quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      stratified according to hemoglobin (&lt; 11g/dL vs ≥ 11 g/dL), alkaline phosphatase (normal vs&#xD;
      elevated), number of prior regimens (0 vs 1 or 2), and ECOG performance score (0 or 1 vs 2).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive docetaxel IV on days 1, 8, 15, and 22 and oral imatinib mesylate&#xD;
           once daily on days 1-43.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel as in arm I and oral placebo once daily on days 1-43.&#xD;
&#xD;
      In both arms, courses repeat every 43 days in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients who progress on arm II may cross over to arm I.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 152 patients (76 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Baseline to 3 years, or until disease progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic effects</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Imatinib Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Docetaxel + Imatinib Mesylate</arm_group_label>
    <arm_group_label>Docetaxel + Placebo</arm_group_label>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <arm_group_label>Docetaxel + Imatinib Mesylate</arm_group_label>
    <other_name>Imatinib</other_name>
    <other_name>Gleevec</other_name>
    <other_name>STI571</other_name>
    <other_name>NSC-716051</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
               -  Osseous metastases confirmed by radiography&#xD;
&#xD;
               -  Lytic bone lesions considered for biopsy if there is clinical suspicion of&#xD;
                  histologic conversion to small cell carcinoma&#xD;
&#xD;
          -  Failed prior hormonal therapy&#xD;
&#xD;
          -  Progressive disease, as evidenced by one of the following:&#xD;
&#xD;
               -  2 consecutive rises in prostate-specific antigen (PSA) of at least 1 ng/mL over 4&#xD;
                  weeks&#xD;
&#xD;
               -  Increase of 25% of the product of bidimensional disease or 30% in maximum&#xD;
                  diameter&#xD;
&#xD;
               -  Increase in number of osseous metastases by bone scan&#xD;
&#xD;
               -  Worsening symptoms attributable to disease progression (e.g., worsening bony&#xD;
                  pain)&#xD;
&#xD;
          -  PSA ≥ 1 ng/mL&#xD;
&#xD;
          -  Castrate serum testosterone ≤ 50 ng/dL&#xD;
&#xD;
               -  Concurrent luteinizing-hormone releasing-hormone analog required for medically&#xD;
                  castrated patients&#xD;
&#xD;
          -  No small cell or sarcomatoid prostate cancers&#xD;
&#xD;
          -  No uncontrolled CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤ 2 times upper limit of&#xD;
             normal&#xD;
&#xD;
          -  No chronic liver disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No evidence of myocardial ischemia on electrocardiogram&#xD;
&#xD;
          -  No uncontrolled severe hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No oxygen-dependent lung disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No concurrent severe infection&#xD;
&#xD;
          -  No contraindication to corticosteroids&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No grade 2 or greater peripheral neuropathy&#xD;
&#xD;
          -  No other malignancy within the past 2 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  No overt psychosis, mental disability, or incompetency that would preclude giving&#xD;
             informed consent&#xD;
&#xD;
          -  No history of noncompliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior taxanes&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 30 days since prior chemotherapy and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide or nilutamide*&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide* NOTE: *Unless there is evidence of interim&#xD;
             disease progression&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 90 days since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam&#xD;
             pentasodium and recovered&#xD;
&#xD;
          -  At least 30 days since other prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Fully recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent ketoconazole&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Mathew</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Logothetis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mathew P, Thall PF, Johnson MM, et al.: Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM). [Abstract] J Clin Oncol 24 (Suppl 18): A-4562, 232s, 2006.</citation>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>October 10, 2012</last_update_submitted>
  <last_update_submitted_qc>October 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

